Back to top

Image: Shutterstock

The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic

Read MoreHide Full Article

For Immediate Release

Chicago, IL – December 11, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Addus HomeCare Corp. (ADUS - Free Report) , Fulgent Genetics, Inc. (FLGT - Free Report) and Hologic, Inc. (HOLX - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

3 MedTech Growth Stocks with Solid Prospects for 2021

The MedTech space has not been left unscathed by the coronavirus rampage that battered the economy for the most part of the year.  

MedTech companies however delivered sturdy performance during the recently concluded earnings season, raising investors’ hopes.

Meanwhile, the ongoing saga surrounding the proposed additional COVID-19 relief package spurs uncertainty. Many economists are of the view that approval of this additional stimulus is only possible if there is a hindrance in vaccine rollout, which would drag down the economy again in 2021.

MedTech 2020 Snapshot

During the last earnings season, the MedTech space put up a mixed performance. Amid the volatile market situation, MedTech companies, which are into diagnostics business, put up a stellar show.

Per a report by CNBC, daily new infections in the country (as a seven-day average) are at an all-time high and quickly approaching 200,000. In this scenario, companies in the diagnostic business are poised to benefit from the surging demand for testing.

MedTech Growth Stocks to Buy Ahead of 2021

Overall, MedTech stocks have adjusted their business models over the past few months and in fact have already started to recover and approach pre-COVID levels. Although it will take some time for the companies to reach the pre-COVID levels of business, it is heartening to witness the steady progress.

As we enter 2021, investors can now choose to invest in stocks, which held their ground amid choppy market conditions and have strong growth potential.

3 Stocks to Buy

We have selected stocks with a Growth Score of A or B. Our research shows that stocks with a Growth Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 (Buy) offer the best upside potential. You can see the complete list of today’s Zacks #1 Rank stocks here.

Our first pick is renowned provider of comprehensive home care services, Addus HomeCare. The company presently carries a Zacks Rank #2 and has a Growth Score of A. It recently closed its acquisition of Queen City Hospice, LLC, and its affiliate Miracle City Hospice, LLC, thus strengthening its presence in its current markets. Its inorganic and organic growth opportunities along with solid third-quarter results inspire optimism in the stock.

Its projected earnings per share (EPS) growth stands at a solid 25.8% versus the industry’s projection of 19.1%. Further, its sales-to-asset ratio stands at an impressive 1.2 compared with the industry’s 0.8. The company projects 20.9% earnings growth for the next year. Year to date, the stock has gained 7.3% compared with the sector’s 4.5% rise.

Our next pick is Fulgent Genetics, a well-known technology company providing comprehensive testing solutions. The company presently sports a Zacks Rank #1 and has a Growth Score of B. The company is riding on strong demand for its COVID-19 tests. Also, the company posted solid third-quarter results amid the pandemic-led challenging business climate.

Its projected EPS growth stands at a stupendously high level compared with the industry’s projection of 3.6%. Further, its return on equity (ROE) stands at an impressive 43.8% against the industry’s negative returns. The company projects 31% earnings growth for the next year. Year to date, the stock has gained 272.2% compared with the industry’s 26.3% rise.

Our final pick is renowned diagnostics player, Hologic. This Zacks Rank #1 company with a Growth Score of B registered growth in the core molecular diagnostics sub-segment in the fourth quarter of fiscal 2020. The company, in October, announced the amendment of the FDA’s Emergency Use Authorization (EUA) that was initially received for its Aptima SARS-CoV-2 assay. It had received the FDA’s EUA for its Panther Fusion SARS-CoV-2 assay in September.

Its projected EPS growth rate currently stands at 68.4% compared with the industry’s 12.2%. Further, its ROE stands at 45.2% against the industry’s negative return. The company projects 68.3% earnings growth for 2021. Year to date, the stock has gained 37.6% compared with the industry’s 19.2% rise.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that have beaten the market more than 2X over with a stunning average gain of +24.4% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Hologic, Inc. (HOLX) - free report >>

Addus HomeCare Corporation (ADUS) - free report >>

FULGENT GENETIC (FLGT) - free report >>